UC Davis to use precision medicine in pancreatic cancer care

Sacramento-based UC Davis Comprehensive Cancer Center will use next generation sequencing analysis on patients diagnosed with hematological malignancies and pancreatic cancer.

Advertisement

The strategy will be deployed through a partnership with Tempus, a health technology company focused on personalized oncology care. Under the partnership, Tempus will work with a team of investigators led by Primo Lara, MD, interim director of the UC Davis Comprehensive Cancer Center.

Tempus will use machine learning and advanced bioinformatics to support physicians as they analyze patient molecular data. The goal of the partnership is to identify patterns to guide treatment for patients who are unlikely to respond to standard therapies.

More articles on data analytics & precision medicine:
Kalorama: Apple, Google, IBM make waves in healthcare analytics market
Intermountain, U of Utah Health to develop EHR clinical decision support under $3.8M NCI grant
University of Rochester Medical Center taps NextGate to aggregate provider data

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

What clinicians need from AI after the pilot: Lessons from Adventist Health and Rady Children’s

Friday, July 24
12:00 PM - 1:00 PM CDT

Presenters: Dr. Dieter Sumerauer, Rady Children’s HealthDr. Salman Naqvi, AdventistDr. Reid Conant, Abridge

Advertisement

Next Up in Digital Health

Advertisement

Comments are closed.